STAT

Protesters’ goodbye for Scott Gottlieb: a supersized heroin spoon and claims FDA did too little on opioids

A parting gift for Scott Gottlieb from a pack of protesters in Washington today: a supersized heroin spoon and allegations the administration has done too little to fight the opioid…

WASHINGTON — Activists on Friday delivered a parting gift to Scott Gottlieb, the outgoing Food and Drug Administration commissioner, at the entrance of a federal building here: an 800-pound, supersized heroin spoon stamped with the FDA’s logo.

The group urged FDA to stop approving “dangerous” opioids and to instead encourage the development of more drugs to treat addiction. Many protesters decried the November approval of Dsuvia, a mega-potent pain drug, and urged the Trump administration to nominate an FDA commissioner who would take a different tack than Gottlieb on opioid approvals.

The protest comes after a series of demonstrations at museums, the now-infamous founders of Purdue Pharma, the manufacturer of OxyContin. But Friday’s event, which took place just five blocks from the Arthur M. Sackler art gallery on the National Mall, marked a shift in protesters’ focus from the pharmaceutical industry to government.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
STAT+: Senate Drug Shortage Bill Would Pay Hospitals Bonuses For Good Contracting Practices
A bipartisan Senate bill takes a new approach to persistent drug shortages: have Medicare pay bonuses to hospitals and physicians for contracting that ensures a steady supply.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About GLP-1 Spending, Biosimilar Patient Costs, And More
Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and they're set to cost the U.S. health care system and the federal government still more.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks